Ayala Pharmaceuticals Inc (AYLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2022 | 06-2022 | 03-2022 | 12-2021 | 09-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -28,425 | -18,237 | -10,027 | -40,254 | -30,205 |
| Depreciation Amortization | 121 | 81 | 30 | 168 | 140 |
| Accounts receivable | -129 | -262 | -638 | 681 | 308 |
| Accounts payable and accrued liabilities | -868 | -308 | -1,140 | -461 | -1,225 |
| Other Working Capital | 48 | -249 | -630 | -954 | -2,463 |
| Other Operating Activity | 2,911 | 1,968 | 2,421 | 2,464 | 2,881 |
| Operating Cash Flow | $-26,342 | $-17,007 | $-9,984 | $-38,356 | $-30,564 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | -5 | -5 |
| Investing Cash Flow | $N/A | $N/A | $N/A | $-5 | $-5 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 512 | 44 | 44 | 33,330 | 29,383 |
| Financing Cash Flow | $512 | $44 | $44 | $33,330 | $29,383 |
| Beginning Cash Position | 37,339 | 37,339 | 37,339 | 42,370 | 42,370 |
| End Cash Position | 11,509 | 20,376 | 27,399 | 37,339 | 41,184 |
| Net Cash Flow | $-25,830 | $-16,963 | $-9,940 | $-5,031 | $-1,186 |
| Free Cash Flow | |||||
| Operating Cash Flow | -26,342 | -17,007 | -9,984 | -38,356 | -30,564 |
| Capital Expenditure | N/A | N/A | N/A | -5 | -5 |
| Free Cash Flow | -26,342 | -17,007 | -9,984 | -38,361 | -30,569 |